135 related articles for article (PubMed ID: 11009218)
1. The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
Hanağasi HA; Kaptanoglu G; Sahin HA; Emre M
Mov Disord; 2000 Sep; 15(5):1016-7. PubMed ID: 11009218
[No Abstract] [Full Text] [Related]
2. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
Varanese S; Howard J; Di Rocco A
Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
[No Abstract] [Full Text] [Related]
3. Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
Fredriksson A; Archer T
Amino Acids; 2002; 23(1-3):111-32. PubMed ID: 12373526
[TBL] [Abstract][Full Text] [Related]
4. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
5. Drug treatments of levodopa-induced dyskinesias.
Vale S
Lancet; 1999 Aug; 354(9177):511. PubMed ID: 10465195
[No Abstract] [Full Text] [Related]
6. Memantine and reduced time with dyskinesia in Parkinson's Disease.
Wictorin K; Widner H
Acta Neurol Scand; 2016 May; 133(5):355-60. PubMed ID: 26234336
[TBL] [Abstract][Full Text] [Related]
7. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
[TBL] [Abstract][Full Text] [Related]
8. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
Morin N; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2010 Jun; 58(7):981-6. PubMed ID: 20074579
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Fredriksson A; Danysz W; Quack G; Archer T
J Neural Transm (Vienna); 2001; 108(2):167-87. PubMed ID: 11314771
[TBL] [Abstract][Full Text] [Related]
10. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
11. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
12. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
14. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
Charvin D; Di Paolo T; Bezard E; Gregoire L; Takano A; Duvey G; Pioli E; Halldin C; Medori R; Conquet F
Mov Disord; 2018 Oct; 33(10):1619-1631. PubMed ID: 30216534
[TBL] [Abstract][Full Text] [Related]
15. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
16. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Hadj Tahar A; Ekesbo A; Grégoire L; Bangassoro E; Svensson KA; Tedroff J; Bédard PJ
Eur J Pharmacol; 2001 Feb; 412(3):247-54. PubMed ID: 11166288
[TBL] [Abstract][Full Text] [Related]
17. Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys.
Hadj Tahar A; Bélanger N; Bangassoro E; Grégoire L; Bédard PJ
Eur J Pharmacol; 2000 Jul; 399(2-3):183-6. PubMed ID: 10884518
[TBL] [Abstract][Full Text] [Related]
18. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman LV; Chase TN; Bonuccelli U
Mov Disord; 2001 May; 16(3):515-20. PubMed ID: 11391748
[TBL] [Abstract][Full Text] [Related]
19. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():27-38. PubMed ID: 25046277
[TBL] [Abstract][Full Text] [Related]
20. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
